Table 1 Ongoing studies of prophylactic surfactant administration via thin catheter.
From: Prophylactic surfactant therapy in the era of less invasive surfactant delivery
Study name, reference | Patient population | Active treatment arm | Comparator group | Primary outcome | Planned sample size |
|---|---|---|---|---|---|
Pro.LISA [35] | 25 0/7 to 28 6/7 weeks’ gestation, supported with CPAP in first hour, FiO2 < 0.30 | Prophylactic surfactant 100–200 mg/kg via thin catheter | Continuation of CPAP, surfactant to be given via thin catheter if FiO2 ≥ 0.30 or if respiratory distress observed by physician | FEV1 at 5 years | 698 infants |
DR LISA [36] (NCT04715373) | 22 0/7 to 25 6/7 weeks’ gestation | Prophylactic surfactant 200 mg/kg via thin catheter | Continuation of CPAP, surfactant to be given via thin catheter if FiO2 ≥ 0.30 while on CPAP of 7 | Need for intubation and/any mechanical ventilation within 72 h | 60 infants |
Premie ProMISe [37] (NCT06007547) | 22 0/7 to 29 6/7 weeks’ gestation, transitioned to CPAP support in the delivery room | Prophylactic surfactant 200 mg/kg within 15 min of birth via thin catheter | Continuation of CPAP, surfactant to be given via thin catheter if FiO2 ≥ 0.30 in first 48 h | Endotracheal intubation within 7 days | 200 infants |
